Get the latest Science News and Discoveries

First made-in-Singapore antibody-drug conjugate EBC-129 progresses to phase 1B dose expansion - EurekAlert

- EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets cancer cells across a range of solid tumours. - The Phase 1 trial for EBC-129 began with a dose escalation study in May 2023. The trial has entered into dose expansion as of 13 May 2024.  - With the initial safety and tolerability of EBC-129 demonstrated in cancer patients, the dose expansion part of the study will further evaluate its effectiveness and tolerability in selected solid tumours.

None

Get the Android app